Literature DB >> 21697477

Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry.

Sheli R Radoshitzky1, Kelly L Warfield, Xiaoli Chi, Lian Dong, Krishna Kota, Steven B Bradfute, Jacqueline D Gearhart, Cary Retterer, Philip J Kranzusch, John N Misasi, Marc A Hogenbirk, Victoria Wahl-Jensen, Viktor E Volchkov, James M Cunningham, Peter B Jahrling, M Javad Aman, Sina Bavari, Michael Farzan, Jens H Kuhn.   

Abstract

With the exception of Reston and Lloviu viruses, filoviruses (marburgviruses, ebolaviruses, and "cuevaviruses") cause severe viral hemorrhagic fevers in humans. Filoviruses use a class I fusion protein, GP(1,2), to bind to an unknown, but shared, cell surface receptor to initiate virus-cell fusion. In addition to GP(1,2), ebolaviruses and cuevaviruses, but not marburgviruses, express two secreted glycoproteins, soluble GP (sGP) and small soluble GP (ssGP). All three glycoproteins have identical N termini that include the receptor-binding region (RBR) but differ in their C termini. We evaluated the effect of the secreted ebolavirus glycoproteins on marburgvirus and ebolavirus cell entry, using Fc-tagged recombinant proteins. Neither sGP-Fc nor ssGP-Fc bound to filovirus-permissive cells or inhibited GP(1,2)-mediated cell entry of pseudotyped retroviruses. Surprisingly, several Fc-tagged Δ-peptides, which are small C-terminal cleavage products of sGP secreted by ebolavirus-infected cells, inhibited entry of retroviruses pseudotyped with Marburg virus GP(1,2), as well as Marburg virus and Ebola virus infection in a dose-dependent manner and at low molarity despite absence of sequence similarity to filovirus RBRs. Fc-tagged Δ-peptides from three ebolaviruses (Ebola virus, Sudan virus, and Taï Forest virus) inhibited GP(1,2)-mediated entry and infection of viruses comparably to or better than the Fc-tagged RBRs, whereas the Δ-peptide-Fc of an ebolavirus nonpathogenic for humans (Reston virus) and that of an ebolavirus with lower lethality for humans (Bundibugyo virus) had little effect. These data indicate that Δ-peptides are functional components of ebolavirus proteomes. They join cathepsins and integrins as novel modulators of filovirus cell entry, might play important roles in pathogenesis, and could be exploited for the synthesis of powerful new antivirals.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21697477      PMCID: PMC3165852          DOI: 10.1128/JVI.02600-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

Review 1.  Functional balance between haemagglutinin and neuraminidase in influenza virus infections.

Authors:  Ralf Wagner; Mikhail Matrosovich; Hans-Dieter Klenk
Journal:  Rev Med Virol       Date:  2002 May-Jun       Impact factor: 6.989

2.  Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes.

Authors:  R L Willey; F Maldarelli; M A Martin; K Strebel
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  A comparison of indirect immunofluorescence and electron microscopy for the diagnosis of some haemorrhagic viruses in cell cultures.

Authors:  A A El Mekki; G van der Groen
Journal:  J Virol Methods       Date:  1981-09       Impact factor: 2.014

4.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

5.  Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus.

Authors:  A Sanchez; M P Kiley; B P Holloway; D D Auperin
Journal:  Virus Res       Date:  1993-09       Impact factor: 3.303

6.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

7.  Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain.

Authors:  C Aiken; J Konner; N R Landau; M E Lenburg; D Trono
Journal:  Cell       Date:  1994-03-11       Impact factor: 41.582

8.  Disulfide bond assignment of the Ebola virus secreted glycoprotein SGP.

Authors:  Laura G Barrientos; Amy M Martin; Pierre E Rollin; Anthony Sanchez
Journal:  Biochem Biophys Res Commun       Date:  2004-10-15       Impact factor: 3.575

9.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.

Authors:  Wenhui Li; Michael J Moore; Natalya Vasilieva; Jianhua Sui; Swee Kee Wong; Michael A Berne; Mohan Somasundaran; John L Sullivan; Katherine Luzuriaga; Thomas C Greenough; Hyeryun Choe; Michael Farzan
Journal:  Nature       Date:  2003-11-27       Impact factor: 49.962

10.  A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2.

Authors:  Swee Kee Wong; Wenhui Li; Michael J Moore; Hyeryun Choe; Michael Farzan
Journal:  J Biol Chem       Date:  2003-12-11       Impact factor: 5.157

View more
  26 in total

1.  Evaluation of perceived threat differences posed by filovirus variants.

Authors:  Jens H Kuhn; Lori E Dodd; Victoria Wahl-Jensen; Sheli R Radoshitzky; Sina Bavari; Peter B Jahrling
Journal:  Biosecur Bioterror       Date:  2011-11-09

Review 2.  Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Authors:  Jin Huk Choi; Maria A Croyle
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

3.  The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus.

Authors:  Aura R Garrison; Barbara G Giomarelli; Calli M Lear-Rooney; Carrie J Saucedo; Srikanth Yellayi; Lauren R H Krumpe; Maura Rose; Jason Paragas; Mike Bray; Gene G Olinger; James B McMahon; John Huggins; Barry R O'Keefe
Journal:  Antiviral Res       Date:  2014-10-05       Impact factor: 5.970

4.  Cell entry by a novel European filovirus requires host endosomal cysteine proteases and Niemann-Pick C1.

Authors:  Melinda Ng; Esther Ndungo; Rohit K Jangra; Yingyun Cai; Elena Postnikova; Sheli R Radoshitzky; John M Dye; Eva Ramírez de Arellano; Ana Negredo; Gustavo Palacios; Jens H Kuhn; Kartik Chandran
Journal:  Virology       Date:  2014-10-11       Impact factor: 3.616

Review 5.  The multiple roles of sGP in Ebola pathogenesis.

Authors:  Marc-Antoine de La Vega; Gary Wong; Gary P Kobinger; Xiangguo Qiu
Journal:  Viral Immunol       Date:  2015-02       Impact factor: 2.257

Review 6.  Neglected filoviruses.

Authors:  Robin Burk; Laura Bollinger; Joshua C Johnson; Jiro Wada; Sheli R Radoshitzky; Gustavo Palacios; Sina Bavari; Peter B Jahrling; Jens H Kuhn
Journal:  FEMS Microbiol Rev       Date:  2016-06-05       Impact factor: 16.408

7.  Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses.

Authors:  Jinhong Chang; Travis K Warren; Xuesen Zhao; Tina Gill; Fang Guo; Lijuan Wang; Mary Ann Comunale; Yanming Du; Dominic S Alonzi; Wenquan Yu; Hong Ye; Fei Liu; Ju-Tao Guo; Anand Mehta; Andrea Cuconati; Terry D Butters; Sina Bavari; Xiaodong Xu; Timothy M Block
Journal:  Antiviral Res       Date:  2013-04-08       Impact factor: 5.970

8.  Ebola Virus Delta Peptide Is a Viroporin.

Authors:  Jing He; Lilia I Melnik; Alexander Komin; Gregory Wiedman; Taylor Fuselier; Cameron F Morris; Charles G Starr; Peter C Searson; William R Gallaher; Kalina Hristova; Robert F Garry; William C Wimley
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

Review 9.  Shedding light on filovirus infection with high-content imaging.

Authors:  Gianluca Pegoraro; Sina Bavari; Rekha G Panchal
Journal:  Viruses       Date:  2012-08-23       Impact factor: 5.048

Review 10.  Potential vaccines and post-exposure treatments for filovirus infections.

Authors:  Brian M Friedrich; John C Trefry; Julia E Biggins; Lisa E Hensley; Anna N Honko; Darci R Smith; Gene G Olinger
Journal:  Viruses       Date:  2012-09-21       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.